| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Protalix BioTherapeutics (AMEX:PLX) is preparing to release its quarterly earnings on Thursday, 2025-08-14. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Protalix BioTherapeutics to report an earnings per share (EPS) of $0.03.
The announcement from Protalix BioTherapeutics is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
Last quarter the company missed EPS by $0.13, which was followed by a 0.0% drop in the share price the next day.
Here's a look at Protalix BioTherapeutics's past performance and the resulting price change:
| Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| EPS Estimate | 0.08 | 0.07 | 0.06 | 0.02 |
| EPS Actual | -0.05 | 0.09 | 0.03 | -0.03 |
| Price Change % | -40.0% | -4.0% | -1.0% | 2.0% |
Shares of Protalix BioTherapeutics were trading at $1.64 as of August 12. Over the last 52-week period, shares are up 70.0%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: PLX
